F. Grange, G. Hedelin, P. Joly, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001
Reviewers: Li Liu, MD
Source: Blood, 93(11), June 1999
Data on prognostic factors of primary cutaneous lymphomas (PCL) other than mycosis fungoides (MF) and the S?zary Syndrome (SS) has been lacking. The well-established factors associated with poor prognosis for nodal lymphomas may not hold true for PCL. Grange and associates conducted this study to test the clinical validity of the EORTC classification and to identify important prognostic factors of survival in patients with non-MF/SS PCL.
A retrospective review of one hundred and fifty-eight patients, median age 68, with diagnoses of non-MF/SS PCL was performed. PCL was defined by the absence of extracutaneous disease detected at the time of diagnosis. Univariate and multivariate analyses for many possible prognostic factors were performed.
Optimal treatments of non-MF/SS PCL remain undefined. Radiation therapy alone can be used in patients with localized CD30 positive large T-cell lymphomas and localized indolent B-cell lymphomas. Multi-agent chemotherapy is more suitable for patients with more advanced disease.
Dec 7, 2010 - Rituximab may be a better option than watchful waiting in some lymphoma patients, and a new treatment option appears effective for relapsed or refractory Hodgkin's lymphoma, according to two studies being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other research being presented will highlight new options for the standard treatment of advanced asymptomatic follicular lymphoma; mantle cell lymphoma; and early, unfavorable Hodgkin's disease.
Apr 1, 2010
Nov 28, 2014